Cyclosporin_NN
A_NN
inhibits_VBZ
monocyte_NN
tissue_NN
factor_NN
activation_NN
in_IN
cardiac_JJ
transplant_NN
recipients_NNS
._.

BACKGROUND_NN
:_:
Fibrin_NN
deposition_NN
and_CC
thrombosis_NN
have_VBP
been_VBN
implicated_VBN
in_IN
both_CC
allograft_NN
rejection_NN
and_CC
vasculopathy_NN
after_IN
cardiac_JJ
transplantation_NN
._.

Because_IN
monocytes_NNS
play_VBP
a_DT
pivotal_JJ
role_NN
in_IN
the_DT
pathophysiology_NN
of_IN
intravascular_JJ
coagulation_NN
activation_NN
through_IN
their_PRP$
ability_NN
to_TO
synthesize_VB
tissue_NN
factor_NN
-LRB-_-LRB-
TF_NN
-RRB-_-RRB-
,_,
we_PRP
asked_VBD
-LRB-_-LRB-
1_LS
-RRB-_-RRB-
whether_IN
monocyte_NN
TF_NN
activation_NN
occurs_VBZ
in_IN
cardiac_JJ
transplant_NN
recipients_NNS
and_CC
-LRB-_-LRB-
2_LS
-RRB-_-RRB-
whether_IN
monocyte_NN
TF_NN
expression_NN
is_VBZ
affected_VBN
by_IN
treatment_NN
with_IN
cyclosporin_NN
A_NN
-LRB-_-LRB-
CsA_NN
-RRB-_-RRB-
._.

METHODS_NNS
AND_CC
RESULTS_NNS
:_:
We_PRP
measured_VBD
levels_NNS
of_IN
TF_NN
activity_NN
in_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
and_CC
highly_RB
purified_VBN
monocytes\/macrophages_NNS
from_IN
10_CD
consecutive_JJ
cardiac_JJ
transplant_NN
recipients_NNS
and_CC
10_CD
healthy_JJ
control_NN
subjects_NNS
._.

TF_NN
activity_NN
generated_VBN
by_IN
both_CC
unstimulated_JJ
and_CC
endotoxin-stimulated_JJ
cells_NNS
was_VBD
significantly_RB
higher_JJR
in_IN
transplant_NN
recipients_NNS
than_IN
in_IN
control_JJ
subjects_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
.05_CD
-RRB-_-RRB-
._.

Increased_VBN
monocyte_NN
TF_NN
expression_NN
in_IN
transplant_NN
recipients_NNS
was_VBD
shown_VBN
to_TO
be_VB
adversely_RB
affected_VBN
by_IN
treatment_NN
with_IN
CsA_NN
:_:
TF_NN
induction_NN
was_VBD
markedly_RB
reduced_VBN
by_IN
CsA_NN
serum_NN
concentrations_NNS
reaching_VBG
peak_JJ
CsA_NN
drug_NN
levels_NNS
._.

Inhibition_NN
of_IN
TF_NN
induction_NN
in_IN
the_DT
presence_NN
of_IN
high_JJ
CsA_NN
blood_NN
concentrations_NNS
was_VBD
also_RB
observed_VBN
when_WRB
stimulation_NN
of_IN
cells_NNS
was_VBD
performed_VBN
with_IN
interferon-gamma_NN
or_CC
interleukin-1beta_NN
._.

As_IN
shown_VBN
by_IN
reverse_JJ
transcription-polymerase_NN
chain_NN
reaction_NN
and_CC
electrophoretic_JJ
mobility_NN
shift_NN
assay_NN
,_,
respectively_RB
,_,
treatment_NN
with_IN
CsA_NN
leads_VBZ
to_TO
decreased_VBN
TF_NN
mRNA_NN
expression_NN
and_CC
reduced_VBD
activation_NN
of_IN
the_DT
NF-kappaB_NN
transcription_NN
factor_NN
,_,
which_WDT
is_VBZ
known_VBN
to_TO
contribute_VB
to_TO
the_DT
induction_NN
of_IN
the_DT
TF_NN
promotor_NN
in_IN
human_JJ
monocytes_NNS
._.

CONCLUSIONS_NNS
:_:
This_DT
study_NN
demonstrates_VBZ
that_IN
TF_NN
activation_NN
,_,
occurring_VBG
in_IN
mononuclear_JJ
cells_NNS
of_IN
cardiac_JJ
transplant_NN
recipients_NNS
,_,
is_VBZ
inhibited_VBN
by_IN
treatment_NN
with_IN
CsA_NN
._.

Inhibition_NN
of_IN
monocyte_NN
TF_NN
induction_NN
by_IN
CsA_NN
may_MD
contribute_VB
to_TO
its_PRP$
successful_JJ
use_NN
in_IN
cardiac_JJ
transplant_NN
medicine_NN
and_CC
might_MD
be_VB
useful_JJ
in_IN
managing_VBG
further_JJ
settings_NNS
of_IN
vascular_JJ
pathology_NN
also_RB
known_VBN
to_TO
involve_VB
TF_NN
expression_NN
and_CC
NF-kappaB_NN
activation_NN
._.

